StockData

China Pharma Holdings, Inc. (CPHI) stock

CPHINYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 18, 2026Score 4/30
$0.50+0.02 (+4.17%)

Close on Nov 17, 2026Market cap $21.51MP/E –Yield –

China Pharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

China Pharma's free cash flow for the twelve months ending Dec 31, 2025 was $88.94K. For fiscal 2025 it was $88.94K. Over ten years it grew -31.7% a year on average. The highest annual figure on record is $27.39M in fiscal 2013.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$88.94K–
FY2024Dec 31, 2024-$444.47K–
FY2023Dec 31, 2023-$711.20K–
FY2022Dec 31, 2022-$811.51K–
FY2021Dec 31, 2021-$687.89K–
FY2020Dec 31, 2020-$909.57K-292.6%
FY2019Dec 31, 2019$472.31K-74.2%
FY2018Dec 31, 2018$1.83M+159.8%
FY2017Dec 31, 2017$704.74K-73.9%
FY2016Dec 31, 2016$2.70M-33.0%
FY2015Dec 31, 2015$4.04M+294.0%
FY2014Dec 31, 2014$1.02M-96.3%
FY2013Dec 31, 2013$27.39M+620.7%
FY2012Dec 31, 2012$3.80M-32.0%
FY2011Dec 31, 2011$5.59M-28.8%
FY2010Dec 31, 2010$7.85M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$151.54K-45.7%
Q3 FY2025Sep 30, 2025-$204.97K–
Q2 FY2025Jun 30, 2025$274.37K-55.2%
Q1 FY2025Mar 31, 2025-$132.00K–
Q4 FY2024Dec 31, 2024$279.23K–
Q3 FY2024Sep 30, 2024-$37.73K–
Q4 FY2022Dec 31, 2022$611.86K–
Q3 FY2022Sep 30, 2022-$33.43K–
Q2 FY2022Jun 30, 2022-$509.11K-189.7%
Q1 FY2022Mar 31, 2022-$880.83K–
Q4 FY2021Dec 31, 2021-$205.17K–
Q3 FY2021Sep 30, 2021-$866.82K–
Q4 FY2020Dec 31, 2020$567.44K–
Q3 FY2020Sep 30, 2020-$483.82K-203.4%
Q2 FY2020Jun 30, 2020-$401.24K-203.7%
Q1 FY2020Mar 31, 2020-$591.95K–
Q4 FY2019Dec 31, 2019-$72.37K-108.4%
Q3 FY2019Sep 30, 2019$468.04K-46.8%
Q2 FY2019Jun 30, 2019$386.96K–
Q1 FY2019Mar 31, 2019-$310.33K-159.7%
Q4 FY2018Dec 31, 2018$856.62K-1.3%
Q3 FY2018Sep 30, 2018$879.94K+32.8%
Q2 FY2018Jun 30, 2018-$425.70K–
Q1 FY2018Mar 31, 2018$520.11K–
Q4 FY2017Dec 31, 2017$867.61K-36.5%
Q3 FY2017Sep 30, 2017$662.52K–
Q2 FY2017Jun 30, 2017-$808.52K–
Q1 FY2017Mar 31, 2017-$16.86K–
Q4 FY2016Dec 31, 2016$1.37M–

More China Pharma figures

See a number that looks wrong?